Free Trial

OnKure Therapeutics Q4 2023 Earnings Report

OnKure Therapeutics logo
$8.61 -0.12 (-1.37%)
(As of 12/18/2024 05:44 PM ET)

OnKure Therapeutics EPS Results

Actual EPS
-$7.00
Consensus EPS
-$5.50
Beat/Miss
Missed by -$1.50
One Year Ago EPS
N/A

OnKure Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

OnKure Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

I was wrong. Dead wrong. (Ad)

I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

Here’s the full story for you.

OnKure Therapeutics Earnings Headlines

Oppenheimer Remains a Buy on OnKure Therapeutics (OKUR)
OnKure Therapeutics announces safety, pharmacokinetic data on OKI-219
This Crypto Is Set to Explode in December
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
OnKure Therapeutics Advances Cancer Drug Trials
See More OnKure Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like OnKure Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on OnKure Therapeutics and other key companies, straight to your email.

About OnKure Therapeutics

Reneo Pharmaceuticals Inc.is a clinical stage pharmaceutical company. It is focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases. Reneo Pharmaceuticals Inc.is based in SAN DIEGO.

View OnKure Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings